← Back to Screener
ABVC BioPharma, Inc. Common Stock (ABVC)
Price$1.23
Favorite Metrics
Price vs S&P 500 (26W)-63.55%
Price vs S&P 500 (4W)1.55%
Market Capitalization$33.33M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)4.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)12.28%
Cash Flow / Share (Quarterly)$-0.12
Price vs S&P 500 (YTD)-41.14%
Gross Margin (TTM)0.25%
Net Profit Margin (TTM)-227.24%
EPS (TTM)$-0.26
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)-6.15%
EPS (Annual)$-0.39
ROI (Annual)-62.44%
Gross Margin (Annual)99.85%
Net Profit Margin (5Y Avg)-2674.08%
Cash / Share (Quarterly)$0.03
Revenue Growth QoQ (YoY)104.47%
ROA (Last FY)-37.55%
Revenue Growth TTM (YoY)56.52%
EBITD / Share (TTM)$-0.28
ROE (5Y Avg)-329.42%
Operating Margin (TTM)-256.03%
Cash Flow / Share (Annual)$-0.12
P/B Ratio3.00x
P/B Ratio (Quarterly)4.66x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)42.86x
Net Interest Coverage (TTM)-5.32x
ROA (TTM)-32.82%
EPS Incl Extra (Annual)$-0.39
Current Ratio (Annual)0.41x
Quick Ratio (Quarterly)0.35x
3-Month Avg Trading Volume0.08M
52-Week Price Return42.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.34
P/S Ratio (Annual)65.40x
Asset Turnover (Annual)0.07x
52-Week High$5.48
Operating Margin (5Y Avg)-2421.44%
EPS Excl Extra (Annual)$-0.39
26-Week Price Return-59.57%
Quick Ratio (Annual)0.35x
13-Week Price Return-37.02%
Total Debt / Equity (Annual)0.14x
Current Ratio (Quarterly)0.41x
Enterprise Value$34.2
Revenue / Share Growth (5Y)-35.78%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-20.65%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)19.33x
Pretax Margin (Annual)-1053.71%
Cash / Share (Annual)$0.03
3-Month Return Std Dev95.21%
Gross Margin (5Y Avg)52.97%
Net Income / Employee (TTM)$-0
ROE (Last FY)-71.17%
Net Interest Coverage (Annual)-11.29x
EPS Basic Excl Extra (Annual)$-0.39
P/FCF (TTM)196.04x
Receivables Turnover (TTM)85.00x
Total Debt / Equity (Quarterly)0.14x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)85.00x
ROI (TTM)-62.81%
P/S Ratio (TTM)41.77x
Pretax Margin (5Y Avg)-2656.65%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.94
Forward P/E0.77x
Price vs S&P 500 (52W)12.56%
Year-to-Date Return-38.50%
5-Day Price Return-8.39%
EPS Normalized (Annual)$-0.39
ROA (5Y Avg)-92.58%
Net Profit Margin (Annual)-962.12%
Month-to-Date Return35.05%
Cash Flow / Share (TTM)$-3.45
EBITD / Share (Annual)$-0.35
Operating Margin (Annual)-873.18%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-181.95%
LT Debt / Equity (Quarterly)0.18x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)247.13x
P/B Ratio (Annual)4.66x
Inventory Turnover (TTM)19.33x
Pretax Margin (TTM)-244.89%
Book Value / Share (Annual)$0.44
Price vs S&P 500 (13W)-37.71%
Beta0.60x
P/FCF (Annual)1110.90x
Revenue / Share (TTM)$0.03
ROE (TTM)-76.44%
52-Week Low$0.81
Analyst Recommendations
Jul 2023
Aug 2023
Sep 2023
Oct 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ABVCABVC BioPharma, Inc. Common Stock | 41.77x | 56.52% | 0.25% | — | $1.23 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
ABVC BioPharma is a clinical-stage biopharmaceutical company developing a pipeline of six drug candidates and a medical device based on botanically-derived therapeutics. The company focuses on proof-of-concept and Phase II clinical trials, leveraging proprietary technology to deliver high efficacy with low toxicity profiles.